Detalles de la búsqueda
1.
Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.
BMC Infect Dis
; 24(1): 99, 2024 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38238680
2.
Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward.
Value Health
; 26(4S): 11-19, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36706952
3.
The Real-World Evidence Workstream in EUreccA 2025: How the Task Was Addressed.
Value Health
; 26(4S): 43-51, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36642216
4.
Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making.
Value Health
; 26(4S): 32-42, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36870678
5.
Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study.
Value Health
; 26(4S): 3-10, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36709042
6.
Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers.
Value Health
; 26(4S): 20-31, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36706951
7.
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.
Liver Int
; 41(6): 1227-1242, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33590598
8.
Appraising research policy instrument mixes: a multicriteria mapping study in six European countries of diagnostic innovation to manage antimicrobial resistance.
Res Policy
; 50(4): 104140, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33941992
9.
Paying for Cures: Perspectives on Solutions to the "Affordability Issue".
Value Health
; 21(3): 276-279, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29566833
10.
Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom.
BMC Med
; 14: 32, 2016 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-26908129
11.
Why has therapy development for dementia failed in the last two decades?
Alzheimers Dement
; 12(1): 60-4, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26710325
12.
Value-based differential pricing: efficient prices for drugs in a global context.
Health Econ
; 24(3): 294-301, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24327269
13.
UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACH.
Int J Technol Assess Health Care
; 31(6): 363-70, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26837803
14.
RELATIVE EFFECTIVENESS IN BREAST CANCER TREATMENT: A HEALTH PRODUCTION APPROACH.
Int J Technol Assess Health Care
; 31(6): 371-9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26788883
15.
How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy, and practice.
Health Res Policy Syst
; 13: 1, 2015 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25552353
16.
Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain.
Clin Transl Oncol
; 26(4): 985-990, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38206517
17.
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries.
Appl Health Econ Health Policy
; 22(3): 297-313, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38214848
18.
Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.
Expert Rev Pharmacoecon Outcomes Res
; 24(4): 509-519, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38284223
19.
Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective.
Expert Rev Pharmacoecon Outcomes Res
; 24(2): 237-250, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38175140
20.
Not one, but many: developing a multi-indication pricing model for medicines in Belgium.
Front Pharmacol
; 14: 1199253, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37841908